{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sun Pharmaceutical Industries Ltd
P/E at 37.01 vs Industry's 36.91: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 37.01 against an industry average of 36.91 represents a marginal premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 8 June 2026. While the one-year return of 22.27% comfortably outpaces the Sensex’s decline of 2.27%, the recent short-term momentum shows signs of strain, with a two-day consecutive fall and underperformance against the sector. The data paints a nuanced picture of valuation and performance across timeframes.
P/E at 37.22 vs Industry's 36.85: What the Data Shows for Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd continues to assert its prominence within the Nifty 50 index, reflecting robust institutional confidence and outperforming key benchmarks. Despite a modest dip in daily trading, the company’s upgraded rating and sustained large-cap status underscore its strategic importance in the Pharmaceuticals & Biotechnology sector.
Sun Pharmaceutical Industries Ltd is Rated Buy
Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Sun Pharmaceutical Industries Ltd: Valuation Shift Signals Renewed Price Attractiveness
Sun Pharmaceutical Industries Ltd has witnessed a notable change in its valuation parameters, moving from a very expensive to an expensive rating. This shift, driven primarily by adjustments in its price-to-earnings and price-to-book value ratios, suggests a recalibration of price attractiveness amid a competitive pharmaceutical sector landscape.
Rs 1,940 Puts — 0.5% Below Current Price — Draw 2,707 Contracts on Sun Pharmaceutical Industries Ltd
Rs 1,940 put options on Sun Pharmaceutical Industries Ltd attracted 2,707 contracts on 3 August 2026, just below the stock’s closing price of Rs 1,950. This surge in put activity invites a closer look at whether it signals protective hedging, bearish positioning, or put writing amid a stock trading near its 52-week high.
P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 38.29 against an industry average of 37.19 reveals a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the company’s rating was reassessed on 8 June 2026. While the one-year return of 20.50% comfortably outpaces the Sensex’s -2.37%, the stock’s recent short-term performance shows signs of pressure, with a 1-day decline of -1.33% and a 1-week drop of -0.53%. The data paints a nuanced picture of valuation and momentum across timeframes.
Sun Pharmaceutical Industries Ltd Gains 2.49%: 5 Key Factors Driving the Week’s Rally
Sun Pharmaceutical Industries Ltd delivered a solid weekly gain of 2.49%, marginally outperforming the Sensex’s 2.39% rise during the week ending 31 July 2026. The stock demonstrated consistent strength, hitting multiple new 52-week and all-time highs amid robust fundamentals, strong technical momentum, and heightened derivatives activity. Despite some softness in recent quarterly earnings, the company’s market leadership and premium valuation underpinned investor confidence throughout the week.
Sun Pharma Q1 FY27: Strong Profit Growth Masks Margin Pressure Concerns
Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic player, reported a robust 27.04% year-on-year surge in consolidated net profit to ₹2,894.79 crores for Q1 FY27 (June 2026 quarter), up from ₹2,278.63 crores in the corresponding quarter last year. On a sequential basis, the company posted a healthy 6.66% quarter-on-quarter growth from ₹2,714.03 crores in Q4 FY26. The stock, with a market capitalisation of ₹4,82,770 crores, closed at ₹1,989.35 on July 31, 2026, down 0.57% on the day following the results announcement.
Sun Pharmaceutical Industries Ltd Hits All-Time High of Rs 2,021 as Momentum Builds Across Timeframes
Sun Pharmaceutical Industries Ltd has reached a significant milestone by touching its all-time high price of Rs. 2,021 on 31 July 2026, marking a new peak in the company’s market valuation and reflecting its sustained strong performance in the Pharmaceuticals & Biotechnology sector.
Broad-Based Technical Strength Lifts Sun Pharmaceutical Industries Ltd to 52-Week High of Rs 2021
With a steady climb over the past five sessions culminating in a 3.72% gain, Sun Pharmaceutical Industries Ltd reached a fresh 52-week high of Rs 2021 on 31 Jul 2026, underscoring robust price momentum supported by a suite of bullish technical indicators.
P/E at 38.63 vs Industry's 37.11: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 38.63 against an industry average of 37.11 indicates a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 8 June 2026. While the one-year return of 17.91% comfortably outpaces the Sensex’s decline of 3.97%, the stock’s consistent gains over recent months suggest a nuanced momentum story worth analysing.
Broad-Based Technical Strength Lifts Sun Pharmaceutical Industries Ltd to 52-Week High of Rs 2009.85
With every major technical indicator aligned to the upside, Sun Pharmaceutical Industries Ltd surged to a fresh 52-week high of Rs 2009.85 on 30 Jul 2026, marking a significant milestone in its price momentum journey.
Sun Pharmaceutical Industries Ltd Hits All-Time High of Rs 2,009.7 as Momentum Builds Across Timeframes
Sun Pharmaceutical Industries Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,009.70 on 30 July 2026, marking a notable achievement in the company’s market journey and reflecting its sustained strong performance within the Pharmaceuticals & Biotechnology sector.
P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has reached a new 52-week and all-time high of ₹1,999.45, underscoring its robust performance and reaffirming its significance as a key constituent of the Nifty 50 index. The stock’s sustained gains and improved institutional interest highlight its growing appeal amid a challenging market backdrop.
Broad-Based Technical Strength Lifts Sun Pharmaceutical Industries Ltd to 52-Week High of Rs 1993.4
With every major moving average and key technical indicator signalling strength, Sun Pharmaceutical Industries Ltd surged to a fresh 52-week high of Rs 1993.4 on 29 Jul 2026, marking a significant milestone in its price momentum journey.
Sun Pharmaceutical Industries Ltd Hits All-Time High of Rs 1,991 as Momentum Builds Across Timeframes
Sun Pharmaceutical Industries Ltd has reached a new all-time high on 29 July 2026, underscoring its sustained growth and robust market presence within the Pharmaceuticals & Biotechnology sector. This milestone reflects the company’s strong fundamentals and consistent performance over recent years.
P/E at 38.05 vs Industry's 36.78: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 38.05 against an industry average of 36.78 represents a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the company’s rating was reassessed on 8 June 2026. The stock’s one-year return of 16.06% comfortably outpaces the Sensex’s decline of 4.75%, yet the data reveals nuanced momentum shifts across shorter timeframes.
Sun Pharmaceutical Industries Ltd Sees Robust Trading Activity Amidst Market Outperformance
Sun Pharmaceutical Industries Ltd has emerged as one of the most actively traded stocks by value on 28 July 2026, demonstrating strong investor interest and institutional participation. The large-cap pharmaceutical giant not only hit a new 52-week and all-time high of ₹1,993 but also outperformed its sector and broader market indices, signalling sustained momentum in a challenging market environment.
Sun Pharmaceutical Industries Ltd Hits All-Time High of Rs 1,988 as Momentum Builds Across Timeframes
Sun Pharmaceutical Industries Ltd has reached a significant milestone by touching an all-time high price of Rs.1988 on 28 Jul 2026, reflecting its robust performance and sustained market confidence within the Pharmaceuticals & Biotechnology sector.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
